JP2023550466A - Prmt5阻害剤としての三環式カルボキサミド誘導体 - Google Patents

Prmt5阻害剤としての三環式カルボキサミド誘導体 Download PDF

Info

Publication number
JP2023550466A
JP2023550466A JP2023530598A JP2023530598A JP2023550466A JP 2023550466 A JP2023550466 A JP 2023550466A JP 2023530598 A JP2023530598 A JP 2023530598A JP 2023530598 A JP2023530598 A JP 2023530598A JP 2023550466 A JP2023550466 A JP 2023550466A
Authority
JP
Japan
Prior art keywords
methyl
amino
carboxamide
quinoline
dihydrofuro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550466A5 (cg-RX-API-DMAC7.html
Inventor
アメガジエ,アルバート
ベイルキン,ダイアン・ジェニファー
ブッカー,ション
ブルボー,マシュー・ポール
バトラー,ジョン・アール
グラッド,サネ・オムホルト・シュレーダー
コーン,トッド・ジェイ
ランマン,ブライアン・アラン
リー,カーシュエ
リウ,チンイエン
ロペス,パトリシア
マンオーニ,フランチェスコ
ナバラトネ,プリマリ・バスンデラ
ペタス,リピング・エイチ
ラヒモフ,レネ
タマヨ,ヌリア・エイ
ベスタガード,ミッケル
ワン,フイ-リン
ウェアーズ,ニコラス・アンソニー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023550466A publication Critical patent/JP2023550466A/ja
Publication of JP2023550466A5 publication Critical patent/JP2023550466A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023530598A 2020-11-24 2021-11-22 Prmt5阻害剤としての三環式カルボキサミド誘導体 Pending JP2023550466A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117937P 2020-11-24 2020-11-24
US63/117,937 2020-11-24
PCT/US2021/060332 WO2022115377A1 (en) 2020-11-24 2021-11-22 Tricyclic carboxamide derivatives as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
JP2023550466A true JP2023550466A (ja) 2023-12-01
JP2023550466A5 JP2023550466A5 (cg-RX-API-DMAC7.html) 2024-11-08

Family

ID=78957958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530598A Pending JP2023550466A (ja) 2020-11-24 2021-11-22 Prmt5阻害剤としての三環式カルボキサミド誘導体

Country Status (17)

Country Link
US (1) US20240101570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251624B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550466A (cg-RX-API-DMAC7.html)
KR (1) KR20230113339A (cg-RX-API-DMAC7.html)
CN (1) CN116783191A (cg-RX-API-DMAC7.html)
AU (1) AU2021386149A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202141A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001461A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007504A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230286A (cg-RX-API-DMAC7.html)
ES (1) ES3058979T3 (cg-RX-API-DMAC7.html)
IL (1) IL302820B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20230113A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006145A (cg-RX-API-DMAC7.html)
PE (1) PE20231312A1 (cg-RX-API-DMAC7.html)
SA (1) SA523440916B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022115377A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532339A (ja) * 2021-08-30 2024-09-05 アムジエン・インコーポレーテツド ナフチリジン誘導体及びその中間体を合成するプロセス

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
LT4263545T (lt) * 2020-12-16 2026-07-27 Amgen Inc. Prmt5 inhibitoriai
CN116462677A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116462676A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
US12552760B2 (en) * 2022-04-22 2026-02-17 The Board Of Trustees Of The University Of Illinois Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof
WO2023246873A1 (zh) * 2022-06-23 2023-12-28 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
US20250376473A1 (en) * 2022-07-01 2025-12-11 Cytosinlab Therapeutics Co., Ltd. Prmts inhibitor and use thereof
CN117362304A (zh) * 2022-07-07 2024-01-09 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用
WO2024012308A1 (zh) * 2022-07-15 2024-01-18 上海和誉生物医药科技有限公司 一种prmt5抑制剂,其制备方法和在药学上的应用
CA3257212A1 (en) * 2022-08-03 2025-03-19 Abbisko Therapeutics Co., Ltd. Fused three-cycle PRMT5 inhibitor containing nitrogen, its preparation process and its pharmaceutical use
EP4567038A4 (en) * 2022-08-09 2025-12-10 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
WO2024038004A1 (en) 2022-08-15 2024-02-22 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
CN121405702A (zh) * 2022-09-26 2026-01-27 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
EP4638436A1 (en) * 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120418246A (zh) * 2022-12-23 2025-08-01 成都微芯药业有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
JP2026504889A (ja) * 2023-01-18 2026-02-10 アンテンジーン・ディスカバリー・リミテッド Prmt5阻害化合物およびその使用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CN120957998A (zh) * 2023-03-30 2025-11-14 百济神州(苏州)生物科技有限公司 作为MTA-协同PRMT5抑制剂的5-氨基-6,8-二氢-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲酰胺衍生物
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2024234821A1 (zh) * 2023-05-17 2024-11-21 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2024240894A1 (en) * 2023-05-24 2024-11-28 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2024245412A1 (en) * 2023-06-02 2024-12-05 Insilico Medicine Ip Limited Prmt5 inhibitors and uses thereof
CN121127465A (zh) 2023-07-14 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN120865197A (zh) * 2023-08-02 2025-10-31 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
WO2025031468A1 (zh) 2023-08-09 2025-02-13 江苏恒瑞医药股份有限公司 杂芳基化合物、其制备方法及其在医药上的应用
CN121127472A (zh) 2023-08-18 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
WO2025113705A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 N-取代酰胺类衍生物抑制剂、其制备方法和应用
WO2025119326A1 (zh) 2023-12-07 2025-06-12 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166260A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025180517A1 (zh) * 2024-03-01 2025-09-04 武汉人福创新药物研发中心有限公司 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途
WO2025218671A1 (en) * 2024-04-16 2025-10-23 Shanghai Apeiron Therapeutics Company Limited Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN119552151B (zh) * 2025-01-24 2025-05-02 赛岚(杭州)生物医药科技有限公司 Prmt5抑制剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153515A1 (en) * 2016-03-09 2017-09-14 Ctxt Pty Limited Tetrahydroisoquinolines as prmt5-inhibitors
JP2020504716A (ja) * 2016-12-22 2020-02-13 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65576B1 (sr) * 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
WO2019209896A1 (en) * 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153515A1 (en) * 2016-03-09 2017-09-14 Ctxt Pty Limited Tetrahydroisoquinolines as prmt5-inhibitors
JP2020504716A (ja) * 2016-12-22 2020-02-13 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE CHEMICAL BIOLOGY, vol. 11, no. 6, JPN6025040934, 2015, pages 432 - 437, ISSN: 0005703237 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532339A (ja) * 2021-08-30 2024-09-05 アムジエン・インコーポレーテツド ナフチリジン誘導体及びその中間体を合成するプロセス

Also Published As

Publication number Publication date
ES3058979T3 (en) 2026-03-16
PE20231312A1 (es) 2023-08-24
CR20230286A (es) 2023-08-24
EP4251624B1 (en) 2025-10-29
IL302820B2 (en) 2026-07-01
IL302820B1 (en) 2026-03-01
AU2021386149A9 (en) 2024-08-08
EP4251624A1 (en) 2023-10-04
SA523440916B1 (ar) 2025-05-07
AU2021386149A1 (en) 2023-06-22
CL2023001461A1 (es) 2023-12-01
CN116783191A (zh) 2023-09-19
US20240101570A1 (en) 2024-03-28
CO2023007504A2 (es) 2023-09-08
WO2022115377A1 (en) 2022-06-02
CA3202141A1 (en) 2022-06-02
JOP20230113A1 (ar) 2023-05-23
IL302820A (en) 2023-07-01
MX2023006145A (es) 2023-06-06
KR20230113339A (ko) 2023-07-28

Similar Documents

Publication Publication Date Title
EP4251624B1 (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
JP7487421B2 (ja) Prmt5阻害剤
JP7787819B2 (ja) 新規prmt5阻害剤
JP2024508235A (ja) 三環-アミド-二環prmt5阻害剤
CN113563309B (zh) 吡啶类衍生物及其制备方法和用途
TW201619150A (zh) 用於調節egfr突變型激酶活性的化合物及組成物
TW202214630A (zh) 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
HK40101523A (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
HK40101523B (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
EA052340B1 (ru) Трициклические карбоксамидные производные в качестве ингибиторов prmt5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260804